Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

UCB is well-positioned to become a key player in the myasthenia gravis market with zilucoplan and rozanolixizumab, says GlobalData

Positive Phase III trial results from UCB’s two clinical trials in its generalized myasthenia gravis (gMG) program will enable it to become a key future player in the MG market, with both zilucoplan and rozanolixizumab expected to enter the market next year, says GlobalData, a leading data and analytics company. Philippa Salter, Neurology Analyst at […]
Read more

Top 20 global biopharmaceutical companies by market capitalization (quarter ended March 31, 2022), presented by GlobalData

The top 20 global biopharmaceutical companies by market capitalization (MCAP) experienced a favorable Q1 2022, despite global economic and financial market uncertainty. The majority of the top 20 global biopharmaceutical companies reported a 2.1% increase in aggregate MCAP, from $3.4 trillion on 31 December 2021 to $3.5 trillion as of 31 March 2022, according to […]
Read more

Complement inhibition is becoming a key neuroimmunology mechanism of action, with pipeline agents spanning numerous indications, says GlobalData

The complement cascade, an arm of the innate immune system consisting of a collection of small proteins with various functions in targeting pathogens, has been implicated in the pathology of a number of different neurological diseases, from autoimmune diseases like myasthenia gravis (MG) to neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), says GlobalData. The leading […]
Read more

Osteoarthritis pipeline shifting from analgesics to disease-modifying treatments as conventional analgesics offer inadequate pain relief, says GlobalData

The current osteoarthritis (OA) market has previously suffered from a lack of effective analgesics and disease-modifying osteoarthritis drugs (DMOADs) partially due to the complex pathophysiology of OA and the lack of appropriate outcome measures for progression of joint damage, says GlobalData. However, the leading data and analytics company notes that drugs that are currently under […]
Read more

Uptake of Adtralza, Rinvoq and Cibinqo for treating atopic dermatitis will be slow in the UK following NICE’s rejection, says GlobalData

Based on the uncertainty relating to the comparison of efficacies of Leo Pharma’s anti-IL-13, Adtralza/Adbry (tralokinumab); AbbVie’s oral Janus kinase (JAK) 1 inhibitor, Rinvoq (upadacitinib); and Pfizer’s oral JAK 1 inhibitor, Cibinqo (abrocitinib) to standard treatments, the UK’s National Institute for Health and Care Excellence (NICE) is not recommending these agents for the treatment of […]
Read more

Neuroimmunology drug development has exploded over the last decade, growing into a dynamic, high-value space, says GlobalData

Over the last decade, the role of the immune system in the etiology and pathophysiology of neurological diseases has steadily gained clarity, says GlobalData. The leading data and analytics company notes that the development of neuroimmunology drugs* has exploded as a result, with the top 20 neuroimmunology products being worth $20.1 billion in 2020 and […]
Read more

Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData

Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) market, achieving around $958 million in sales by 2025, according to GlobalData, a leading data and analytics company. Sarah Bundra, Pharmaceutical Analyst at GlobalData, comments: “Mavacamten will be the first drug to specifically target obstructive HCM, which is a common form of cardiomyopathy. […]
Read more

Digital diabetes care support on rise in India, observes GlobalData

Diabetes has reached epidemic proportions over the last three decades and India continues to have the second-largest number of adults with diabetes worldwide, after China. Consequently, lifestyle management is a  crucial step in improving  patient outcomes and metabolic parameters associated with the disease. In this context, various pharmaceutical companies and healthtech companies are offering personalized […]
Read more

Current treatments for diabetic complication macular edema still not effective enough despite influx of new drugs, says GlobalData

While there have been several significant steps forward when it comes to treating diabetes complication diabetic macular edema (DME) this year, current therapies are still not effective enough, according to GlobalData. The leading data and analytics company notes that not only is there still a surplus of unmet needs, but current therapies still have quite […]
Read more

Russian companies involved in innovator drug licensing agreement remains low, says GlobalData

Over the past five years, very few licensing agreements for innovator drugs have involved Russian biopharmaceutical companies where the majority involve drugs that are marketed, says GlobalData. The leading data and analytics company notes that these licensing agreements include the commercialization, manufacturing, and/or distribution of innovator drugs involving Russian biopharmaceutical companies from 2017 to 2021. […]
Read more

Axsome Therapeutics’ migraine treatment AXS-07 faces many hurdles before FDA approval, says GlobalData

Axsome Therapeutics expects to receive a complete response letter (CRL) from the FDA due to the recently revealed chemistry, manufacturing, and control (CMS) issues identified during the FDA’s review of its new drug application for AXS-07 (rizatriptan and meloxicam), for the acute treatment of migraines. According to GlobalData’s report, ‘Migraine Drug Market Size, Share & Trends Analysis […]
Read more

Mavacamten will achieve a dominant share of hypertrophic cardiomyopathy market as it significantly improves patients’ quality of life, says GlobalData

At the 71st annual American College of Cardiology (ACC) 2022 meeting, results were presented from MAVA-LTE, the ongoing five-year study of mavacamten in obstructive hypertrophic cardiomyopathy (oHCM). Based on these results, mavacamten will likely dominate the oHCM market as the first-in-class cardiac myosin inhibitor and rapidly steal market share from the non-specific therapies that are […]
Read more
1 … 46 47 48 49 50 … 108